Simultaneous vaccination against seasonal influenza and COVID-19 among the target population in Italy.

Vincenza Sansone, Grazia Miraglia Del Giudice, Giorgia Della Polla, Italo Francesco Angelillo
Author Information
  1. Vincenza Sansone: Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
  2. Grazia Miraglia Del Giudice: Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
  3. Giorgia Della Polla: Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
  4. Italo Francesco Angelillo: Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.

Abstract

Introduction: Annual influenza and COVID-19 vaccinations are effective tools for reducing the disease burden. The goals of the present cross-sectional survey were to investigate attitudes and behaviors toward the simultaneous vaccination against seasonal influenza and COVID-19 and the factors associated.
Methods: Questionnaires were self-administered or researcher-administered between October 2023 and February 2024 in an immunization center in the southern part of Italy.
Results: All 151 subjects eligible for influenza and COVID-19 vaccinations who attended the center agreed to participate. A total of 59.9% of respondents received concurrent seasonal influenza and COVID-19 vaccinations. Those who perceived that the simultaneous vaccination was safer and those who have been infected by SARS-CoV-2 fewer times were more likely to have simultaneously received both vaccinations. Regarding the reasons reported, half of the sample stated that the simultaneous vaccination was safe and that they were adequately informed. This was more likely indicated by the respondents who had received at least four doses of the COVID-19 vaccination. Among those who had not received the simultaneous vaccination, 70.7% and 29.3% had received only seasonal influenza and COVID-19.
Conclusion: Educational health communication campaigns are necessary to improve compliance with simultaneous administration of seasonal influenza and COVID-19 vaccinations and to increase the unsatisfactory coverage.

Keywords

References

  1. J Pers Med. 2022 Jan 20;12(2): [PMID: 35207628]
  2. Clin Microbiol Infect. 2024 May;30(5):653-659 [PMID: 38253313]
  3. Vaccines (Basel). 2021 Nov 25;9(12): [PMID: 34960144]
  4. Sci Rep. 2024 Feb 22;14(1):4369 [PMID: 38388666]
  5. Hum Vaccin Immunother. 2023 Aug 1;19(2):2252708 [PMID: 37706326]
  6. Vaccines (Basel). 2021 Sep 13;9(9): [PMID: 34579253]
  7. BMC Public Health. 2021 Apr 28;21(1):818 [PMID: 33910558]
  8. Front Public Health. 2024 Mar 04;12:1321173 [PMID: 38500722]
  9. Vaccines (Basel). 2022 Dec 21;11(1): [PMID: 36679863]
  10. Hum Vaccin Immunother. 2021 Jun 3;17(6):1612-1621 [PMID: 33242386]
  11. Hum Vaccin Immunother. 2023 Dec 31;19(1):2188856 [PMID: 36988622]
  12. J Community Health. 2023 Aug;48(4):731-739 [PMID: 37002473]
  13. Vaccines (Basel). 2024 Mar 20;12(3): [PMID: 38543970]
  14. Vaccine. 2023 Feb 3;41(6):1190-1197 [PMID: 36585281]
  15. Vaccine. 2022 Feb 16;40(8):1152-1161 [PMID: 35078659]
  16. JAMA Netw Open. 2023 Nov 1;6(11):e2342151 [PMID: 37938846]
  17. Hum Vaccin Immunother. 2024 Dec 31;20(1):2327229 [PMID: 38497583]
  18. Am J Prev Med. 2024 Jul;67(1):67-78 [PMID: 38401746]
  19. Vaccines (Basel). 2021 Jun 24;9(7): [PMID: 34202867]
  20. Vaccines (Basel). 2023 Aug 27;11(9): [PMID: 37766100]
  21. Vaccine. 2024 Apr 30;42(12):3107-3114 [PMID: 38604912]
  22. Eur J Public Health. 2023 Dec 9;33(6):1183-1187 [PMID: 37632235]
  23. Vaccine. 2023 Sep 7;41(39):5678-5682 [PMID: 37599140]
  24. Hum Vaccin Immunother. 2022 Dec 31;18(1):1-2 [PMID: 34893012]
  25. Vaccine. 2023 Mar 10;41(11):1859-1863 [PMID: 36669964]
  26. BMJ Open. 2022 Jan 3;12(1):e057127 [PMID: 34980631]
  27. Vaccine. 2024 Apr 2;42(9):2166-2170 [PMID: 38514356]
  28. Am J Infect Control. 2022 Mar;50(3):262-267 [PMID: 34995722]
  29. Hum Vaccin Immunother. 2024 Dec 31;20(1):2310916 [PMID: 38369712]
  30. Lancet Reg Health West Pac. 2022 Oct;27:100540 [PMID: 35892009]
  31. Vaccine. 2023 Nov 30;41(49):7342-7347 [PMID: 37957038]
  32. Vaccines (Basel). 2023 Mar 27;11(4): [PMID: 37112649]
  33. Vaccine. 2024 May 31;42(15):3499-3504 [PMID: 38641495]
  34. BMJ Open. 2023 Dec 7;13(12):e079115 [PMID: 38149414]
  35. Vaccines (Basel). 2021 Mar 18;9(3): [PMID: 33803730]
  36. Front Public Health. 2023 Jul 27;11:1163617 [PMID: 37575117]
  37. Healthcare (Basel). 2023 Jan 24;11(3): [PMID: 36766916]
  38. Vaccines (Basel). 2022 Aug 04;10(8): [PMID: 36016141]
  39. Ann Med. 2023;55(2):2286339 [PMID: 38019773]
  40. Nat Hum Behav. 2022 Dec;6(12):1634-1648 [PMID: 35995837]
  41. Open Forum Infect Dis. 2024 Mar 13;11(4):ofae144 [PMID: 38567194]

MeSH Term

Humans
Italy
Male
Female
Influenza, Human
Cross-Sectional Studies
Influenza Vaccines
COVID-19
Middle Aged
Adult
COVID-19 Vaccines
Surveys and Questionnaires
Aged
Vaccination
SARS-CoV-2
Seasons
Health Knowledge, Attitudes, Practice
Young Adult

Chemicals

Influenza Vaccines
COVID-19 Vaccines

Word Cloud

Created with Highcharts 10.0.0COVID-19influenzavaccinationsimultaneousvaccinationsseasonalreceivedItalysurveycenterrespondentslikelyIntroduction:Annualeffectivetoolsreducingdiseaseburdengoalspresentcross-sectionalinvestigateattitudesbehaviorstowardfactorsassociatedMethods:Questionnairesself-administeredresearcher-administeredOctober2023February2024immunizationsouthernpartResults:151subjectseligibleattendedagreedparticipatetotal599%concurrentperceivedsaferinfectedSARS-CoV-2fewertimessimultaneouslyRegardingreasonsreportedhalfsamplestatedsafeadequatelyinformedindicatedleastfourdosesAmong707%293%Conclusion:EducationalhealthcommunicationcampaignsnecessaryimprovecomplianceadministrationincreaseunsatisfactorycoverageSimultaneousamongtargetpopulation

Similar Articles

Cited By